Innovo Bioanalysis
Provides contract bioanalytical research services and develops mass spectrometry–based bioanalytical methodology to identify biomarkers, characterize metabolites, and support DMPK/PK/PD/TK and safety assessments for drug discovery and development. Engages in collaborative research with academic and industry partners and publishes methods for cross-species metabolite and biomarker analysis.
Industries
Nr. of Employees
small (1-50)
Innovo Bioanalysis
Products
Contract Bioanalytical Research Services
Provides bioanalytical research using LC/MS/MS for analysis of drugs, metabolites, and biomarkers to support pharmacokinetics, pharmacodynamics, drug metabolism, and toxicokinetics studies.
Bioanalytical Method Development
Develops and validates bioanalytical methods for quantifying drugs, metabolites, and biomarkers in biological matrices using advanced mass spectrometry techniques.
Biomarker Analysis in Biological Fluids and Target Tissues
Analyzes biomarkers in biological fluids and tissues, including in vivo and in vitro assays for transporters, cytochrome P450 enzymes, and pharmacological biomarkers.
Pharmacokinetic (PK) and Toxicokinetic (TK) Analysis
Conducts pharmacokinetic and toxicokinetic analyses to measure drug and metabolite concentrations over time in biological samples for safety and efficacy evaluation.
Metabolite in Safety Testing (MIST) Coverage Assessments
Performs assessments to determine exposure coverage of drug metabolites in safety testing across species using bioanalytical techniques.
Contract Bioanalytical Research Services
Provides bioanalytical research using LC/MS/MS for analysis of drugs, metabolites, and biomarkers to support pharmacokinetics, pharmacodynamics, drug metabolism, and toxicokinetics studies.
Bioanalytical Method Development
Develops and validates bioanalytical methods for quantifying drugs, metabolites, and biomarkers in biological matrices using advanced mass spectrometry techniques.
Biomarker Analysis in Biological Fluids and Target Tissues
Analyzes biomarkers in biological fluids and tissues, including in vivo and in vitro assays for transporters, cytochrome P450 enzymes, and pharmacological biomarkers.
Pharmacokinetic (PK) and Toxicokinetic (TK) Analysis
Conducts pharmacokinetic and toxicokinetic analyses to measure drug and metabolite concentrations over time in biological samples for safety and efficacy evaluation.
Metabolite in Safety Testing (MIST) Coverage Assessments
Performs assessments to determine exposure coverage of drug metabolites in safety testing across species using bioanalytical techniques.
Services
Design and execution of bioanalysis for drugs, metabolites, and biomarkers to support DMPK, PK/PD and safety assessments.
Analytical measurement of biomarkers in biological fluids and a variety of target tissues for translational research and drug development.
Design and execution of bioanalysis for drugs, metabolites, and biomarkers to support DMPK, PK/PD and safety assessments.
Analytical measurement of biomarkers in biological fluids and a variety of target tissues for translational research and drug development.
Expertise Areas
- Mass spectrometry–based bioanalysis
- Bioanalytical method development
- Biomarker discovery and quantitation
- DMPK / PK / PD analysis
Key Technologies
- Mass spectrometry
- Liquid chromatography–tandem mass spectrometry (LC–MS/MS)
- Ultra-high-performance liquid chromatography with high-resolution MS (UHPLC–HRMS)
- Untargeted metabolomics / unbiased scanning
News & Updates
Company leadership chaired a session on discovery bioanalysis and new technologies at the 14th Annual Applied Pharmaceutical Analysis Meeting.
Company leadership presented at a symposium focused on contributions of women scientists to drug metabolism, drug transporter, and pharmacokinetics research.
Publication describing IVIVE approaches for transporter-mediated drug–drug interactions.
Study reporting potential novel biomarkers identified via metabolite profiling in dosed animals.
Method publication on untargeted UHPLC–HRMS scanning and data-banking for cross-study metabolite comparison.
Company leadership chaired a session on discovery bioanalysis and new technologies at the 14th Annual Applied Pharmaceutical Analysis Meeting.
Company leadership presented at a symposium focused on contributions of women scientists to drug metabolism, drug transporter, and pharmacokinetics research.
Publication describing IVIVE approaches for transporter-mediated drug–drug interactions.
Study reporting potential novel biomarkers identified via metabolite profiling in dosed animals.
Method publication on untargeted UHPLC–HRMS scanning and data-banking for cross-study metabolite comparison.